Sector News

Eli Lilly to buy Boehringer Ingelheim pet vaccines portolio

October 11, 2016
Life sciences

Eli Lilly & Co. is buying Boehringer Ingelheim Vetmedica Inc.’s U.S. pet vaccines portfolio for $885 million as it continues to grow its animal unit.

Lilly’s animal-health subsidiary, Elanco U.S., is buying the portfolio of cat, dog and rabies vaccines, which includes drugs to prevent Lyme disease and Canine Infectious Respiratory Disease.

“We understand the unique bond that owners share with pets and are committed to helping those pets live longer, healthier lives,” said Elanco Animal Health President Jeff Simmons.

The deal also includes a Fort Dodge, Iowa, manufacturing and research site, with an on-site veterinary research center, and several potential drugs in the research pipeline.

Lilly has expanded its animal medicine division in recent years, buying Novartis AG’s animal-health business for $5.4 billion in early 2015. The animal health unit brought in $3.18 billion in revenue for Lilly in 2015.

The move is required for an asset swap with French pharmaceutical company Sanofi to move forward. Sanofi is exchanging its animal health business Merial for Boehringer Ingelheim’s consumer health-care unit and cash.

The deal is expected to close by early 2017 and subject to approval by the Federal Trade Commission, antitrust regulators and the closing of the Sanofi asset swap.

Lilly expects the deal to add to adjusted earnings in 2018 and to as-reported earnings in 2019.

By Austen Hufford

Source: Wall Street Journal

Related News

June 13, 2021

Making drug-resistant bacteria susceptible to antibiotics

Life sciences

Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.

June 13, 2021

Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck

Life sciences

Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.

June 13, 2021

Beigene expands into cancer cell therapy with Shoreline pact

Life sciences

Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.

Send this to a friend